| Praveen P. Tipirneni |
Praveen P. Tipirneni is currently the Chief Executive Officer & Director at Morphic Therapeutic, Inc. and Morphic Holding, Inc. He is also a Director at Tectonic Therapeutic, Inc. and an Independent Director at Panacea Acquisition Corp. II. Previously, he served as the Chief Executive Officer & Director at Morphic Holding, Inc. from 2015 to 2023. He also held positions as Principal at Sun Microsystems, Inc. and Fusion MPHC Group, Inc. (Delaware), as well as Corporate Development Manager at Deltagen, Inc. Prior to that, he was the Senior VP-Corporate Development & Global Strategy at Cubist Pharmaceuticals LLC from 2002 to 2015. Dr. Tipirneni holds a doctorate degree from McGill University, an undergraduate degree from Massachusetts Institute of Technology, and an MBA from The Wharton School of the University of Pennsylvania. |
| Blaise Lippa |
Blaise Lippa is currently the Chief Scientific Officer at Morphic Therapeutic, Inc. since 2015 and at Morphic Holding, Inc. since 2022. Previously, Blaise worked as the Senior Director-Medicinal Chemistry at Cubist Pharmaceuticals LLC. Blaise holds a doctorate degree from Stanford University and an undergraduate degree from the University of Michigan. |
| Marc Schegerin |
Marc Schegerin is currently an Independent Director at SQZ Biotechnologies Co., Chief Financial & Operating Officer at Morphic Therapeutic, Inc., and Chief Operating & Financial Officer at Morphic Holding, Inc. Previously, he worked as a Program Director at Biogen, Inc. from 2009 to 2013, a Director at Citigroup, Inc. from 2016 to 2018, a Senior Director at SAGE Therapeutics, Inc. from 2013 to 2014, and as the Chief Financial Officer, Treasurer & Head-Strategy at ArQule, Inc. from 2019 to 2020. He obtained his undergraduate degree from Tulane University (Louisiana), a doctorate from Dartmouth Medical School, an MBA from Tuck School of Business at Dartmouth, and another undergraduate degree from Harvard University. |
| Bruce N. Rogers |
Bruce N. Rogers is currently the President at Morphic Holding, Inc. since 2024 and the President at Morphic Therapeutic, Inc. since 2022. Previously, he worked as the Head-Neuro Opportunities at Pfizer Inc. from 2014 to 2016 and as a Scientist at Pharmacia & Upjohn Co. LLC from 1998 to 2003. Dr. Rogers holds a doctorate degree from the University of California, Irvine and an undergraduate degree from the University of Minnesota. |
| Robert E. Farrell |
Robert E. Farrell's current job(s) include serving as the Treasurer & Chief Accounting Officer at Morphic Holding, Inc. since 2020, and as the Chief Accounting Officer & Senior Vice President at Morphic Therapeutic, Inc. since 2015. Mr. Farrell's former job(s) include working as the Senior Director-Finance at PPD Dermatology LLC, as the Controller at Oscient Pharmaceuticals Corp., as the Vice President-Finance at NeoGenesis Pharmaceuticals, Inc., and as the Treasurer & VP-Finance & Administration at Genocea Biosciences, Inc. from 2009 to 2015. Mr. Farrell obtained his undergraduate degree from Bentley University. |
| Gustav A. Christensen |
Gustav A. Christensen is currently the Chairman at Morphic Therapeutic, Inc., Chairman at Morphic Holding, Inc., President, Treasurer & Director at Phytera, Inc., and Independent Director at Generation Bio Co. Previously, he held positions such as President, Chief Executive Officer & Director at Dyax Corp., Chairman at Alpha-Beta Technology, Inc., Managing Director at Apeiron Partners LLC, Vice President-Business Development at Genetics Institute LLC, President at ImmuLogic Pharmaceutical Corp., Advisor at BioVentures Investors, Member-Management Board at Alantos Pharmaceuticals AG, and Vice President-Operations Fenwal Laboratories at Baxter International, Inc. He has a graduate degree from the University of Aarhus and an MBA from Harvard Business School. |
| Simon Cooper |
Simon Cooper is currently the Chief Medical Officer at Morphic Therapeutic, Inc. and Morphic Holding, Inc. He previously worked as the Global Program Medical Director at Novartis International AG from 2012 to 2014. In 2021, he served as the Chief Medical Officer & Senior Vice President at Kadmon Holdings, Inc. He also held the position of VP, Global Project Head-Immunology & Inflammation at Sanofi SA. From 2021 to 2024, he was the Chief Medical Officer at Keros Therapeutics, Inc. Prior to that, he worked as the Chief Medical Officer at Anokion US, Inc. from 2019 to 2021. Dr. Cooper completed his undergraduate degree at Newcastle University Medical School. |
| Brihad Abhyankar |
Brihad Abhyankar is currently working as the Vice President of Clinical Development at Morphic Holding, Inc. and Morphic Therapeutic, Inc. He previously worked as the Medical Director of Clinical Sciences at Takeda Pharmaceuticals Europe Ltd. from 2012 to 2015, as the Medical Director at Theravance Biopharma US, Inc. from 2017 to 2022, and as the Head of Clinical Development at Akari Therapeutics Plc in 2016. He completed his undergraduate and graduate studies at the University of Mumbai and holds an MBA from Henley Management College. |
| Nisha Nanda |
Nisha Nanda is an Independent Director at Morphic Holding, Inc. She previously worked as a Senior Director-Clinical Science at Onyx Pharmaceuticals, Inc. from 2012 to 2014. She then served as the Chief Development Officer at Loxo Oncology, Inc. from 2019 to 2023. Dr. Nanda holds undergraduate and doctorate degrees from The University of New South Wales. |
| Norbert W. Bischofberger |
Norbert W. Bischofberger is the founder of Rezo Therapeutics, Inc. (founded in 2022) where he holds the title of Director. He is currently the President, Chief Executive Officer & Director at Kronos Bio, Inc. (since 2018), an Independent Director at Morphic Holding, Inc. (since 2019), a Director at Morphic Therapeutic, Inc. (since 2019), and an Independent Member-Supervisory Board at Bayer AG (since 2017). He is also a Scientific Advisor at VV Manager LLC. Dr. Bischofberger previously worked as a Director at InCarda Therapeutics, Inc. He held the position of Chief Scientific Officer & Executive VP- Research at Gilead Sciences, Inc. from 2007 to 2018. Prior to that, he was the Manager-DNA Synthesis Group at Genentech, Inc. from 1986 to 1990. Dr. Bischofberger obtained a doctorate degree from the Swiss Federal Institute of Technology in 1983 and an undergraduate degree from the University of Innsbruck in 1980. |
| Joseph P. Slattery |
Joseph P. Slattery's current jobs include being the Lead Independent Director at CVRx, Inc., an Independent Director at Replimune Group, Inc., a Director at Morphic Therapeutic, Inc., an Independent Director at Morphic Holding, Inc., and a Member of the Virginia Society of Certified Public Accountants. Mr. Slattery's former jobs include being an Independent Director at Amgen Rockville, Inc. from 2011 to 2012, a Director at Exosome Diagnostics, Inc. from 2013 to 2018, a Director at Baxano Surgical, Inc., an Independent Director at Omega Alpha SPAC, a Director at Micromet Inc., the Chief Financial Officer & SVP-Information Systems at Digene Corp. from 2006 to 2007, a Staff Auditor at Ernst & Young LLP, an Audit Manager at KPMG LLP, the CFO, Executive VP & Head-Investor Relations at TranS1, Inc. from 2012 to 2013, the Chief Financial Officer & Executive Vice President at SafeStitch Medical, Inc. in 2013, the CFO, Secretary, Treasurer & Executive VP at Baxano Surgical, Inc. from 2013 to 2013, the CFO, Chief Accounting Officer & EVP at Asensus Surgical, Inc. from 2013 to 2019, and the Chief Financial Officer & Executive Vice President at TransEnterix, Inc. from 2013 to 2019. Mr. Slattery obtained his undergraduate degree from Bentley University in 1987. |
| Amir H. Nashat |
Amir H. Nashat is the founder of Living Proof, Inc. (founded in 2004) and Alioth, Inc. (founded in 2018). He held the title of Chief Executive Officer & Director at Living Proof, Inc. from 2004 to 2011. Currently, he is the Chief Executive Officer & Director at Soufflé Therapeutics, Inc. and the Co-Chairman at Dewpoint Therapeutics, Inc. He is also the Chairman of Paratus Sciences Corp. starting in 2024. Additionally, he holds director positions at TARIS BioMedical LLC, Partners Innovation Fund LLC, AgBiome INC, Scholar Rock, Inc., Freenome Holdings, Inc., Morphic Holding, Inc., Primmune Therapeutics, Inc., Scholar Rock Holding Corp., Institute For Protein Innovation, Inc., Aliothtalent, Kojin Therapeutics, Inc., Brain Games Corp., Camp4 Therapeutics Corp., Morphic Therapeutic, Inc., and Polaris Growth Management LLC (since 2002). Previously, he served as the Chief Executive Officer of aTyr Pharma, Inc., Sun Catalytix Corp., Olivo Laboratories LLC, and Jnana Therapeutics, Inc. He was also a director at Athenix Corp., GI Dynamics, Inc., Pervasis Therapeutics, Inc., DNIB Unwind, Inc., CubicPV, Inc., Selecta Biosciences, Inc., Receptos LLC, KinDex Pharmaceuticals, Inc., Adnexus, Hydra Biosciences, Inc., WaveRx, Inc., Avila Therapeutics, Inc., New England Venture Capital Association, Inc., Fate Therapeutics, Inc., T2 Biosystems, Inc., L1 AgroSciences, Inc., Quintiles Biosciences, Inc., Syros Pharmaceuticals, Inc. (from 2014 to 2022), Metacrine, Inc. (from 2015 to 2023), Sofregen Medical, Inc., Pax Healthcare, Taris Holdings LLC, and Promedior, Inc. (from 2008 to 2018). Dr. Nashat obtained a doctorate degree from the Massachusetts Institute of Technology in 2002. He also holds undergraduate and graduate degrees from the University of California, Berkeley, conferred in 1994 and 1996 respectively. |
| Susannah Gray |
Ms. Susannah Gray is an Independent Director at Theravance Biopharma, Inc., an Independent Director at Morphic Holding, Inc., an Independent Director at Maravai Lifesciences Holdings, Inc. and an Independent Director at 4D Molecular Therapeutics, Inc. She is on the Board of Directors at Theravance Biopharma, Inc., Morphic Holding, Inc., Morphic Therapeutic, Inc., Maravai Lifesciences Holdings, Inc., 4D Molecular Therapeutics, Inc., Biosplice LLC, Biosplice Therapeutics, Inc., Colby College Museum of Art, Maravai Life Sciences, Inc., StreetSquash, Susan G. Komen Foundation, The German Marshall Fund of United States and Wesleyan University. Ms. Gray was previously employed as an Independent Director by Apria, Inc., an Executive Vice President-Finance & Strategy by Royalty Pharma Management LLC, an Executive Vice President-Finance & Strategy by RP Management LLC, an Analyst by CIBC World Markets Corp. (Old), and a Managing Director by Merrill Lynch & Co., Inc. /Old/. She also served on the board at Susan G. Komen for the Cure. She received her undergraduate degree from Wesleyan University and an MBA from Columbia Business School. |
| Martin W. Edwards |
Martin W. Edwards founded Epsilon-3 Bio Ltd in 2010, where he is working as Chairman from 2015. Dr. Edwards also currently works at Karus Therapeutics Ltd., as Non-Executive Director, Verona Pharma Plc, as Independent Non-Executive Director from 2019, Vantia Ltd., as Director from 2008, and various other companies. Dr. Edwards also formerly worked at ReNeuron Group Plc, as Chief Executive Officer from 1998 to 2003, ReNeuron Ltd., as Chief Executive Officer from 1998 to 2003, Symphogen A, as Chairman, and various other companies. Dr. Edwards received his undergraduate degree and doctorate degree from The University of Manchester and Masters Business Admin degree from the University of Warwick. |
| Timothy A. Springer |
Timothy A. Springer is the founder of LeukoSite, Inc. (1993), Morphic Holding, Inc. (2014), Scholar Rock Holding Corp. (2012), Institute For Protein Innovation, Inc. (2017), and Morphic Therapeutic, Inc. (2014). Dr. Springer was also the founder of Scholar Rock, Inc., Tectonic Therapeutic, Inc... Dr. Springer's current job(s) included being a Director at Seismic Therapeutic, Inc. (2022-present), Cartesian Therapeutics, Inc. (2023-present), and a Member of the National Academy of Sciences, The American Association of Immunologists, and a Trustee at The Marine Biological Laboratory. Dr. Springer's former job(s) include being an Independent Director at Selecta Biosciences, Inc. and a Professor at The Children's Hospital Corp. Dr. Springer's education history includes a doctorate degree from Harvard University and an undergraduate degree from the University of California, Berkeley. |
